Reduced PPARγ expression was demonstrated in lung fibroblasts from patients with SSc [22, 53] and in alveolar macrophages of patients with sarcoidosis [54] and pulmonary alveolar proteinosis [55], suggesting that insufficient PPARγ activity may contribute to ongoing dysregulated inflammation and fibrosis. Here, PPARG is linked to systemic sclerosis.